NCT02621398View on ClinicalTrials.gov

Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

August 4, 2016

Primary Completion Date

October 24, 2019

Study Completion Date

December 30, 2042

Conditions
Stage II Non-Small Cell Lung CancerStage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung Cancer
Interventions
RADIATION

3-Dimensional Conformal Radiation Therapy

Undergo 3D-CRT or IMRT

DRUG

Carboplatin

Given IV

RADIATION

Intensity-Modulated Radiation Therapy

Undergo 3D-CRT or IMRT

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Paclitaxel

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (3)

19104

University of Pennsylvania/Abramson Cancer Center, Philadelphia

06510

Yale Cancer Center, New Haven

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Rutgers Cancer Institute of New Jersey

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Rutgers, The State University of New Jersey

OTHER